Edgewise Therapeutics (EWTX) Expected to Announce Quarterly Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Edgewise Therapeutics to post earnings of ($0.39) per share for the quarter.

Edgewise Therapeutics Stock Down 0.1 %

EWTX traded down $0.03 on Friday, reaching $27.07. The company had a trading volume of 1,115,381 shares, compared to its average volume of 925,280. Edgewise Therapeutics has a 1 year low of $14.90 and a 1 year high of $38.12. The stock has a market capitalization of $2.56 billion, a PE ratio of -18.05 and a beta of 0.20. The stock has a 50-day moving average price of $27.59 and a 200-day moving average price of $27.20.

Insiders Place Their Bets

In related news, CEO Kevin Koch sold 8,636 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $30.03, for a total value of $259,339.08. Following the sale, the chief executive officer now directly owns 14,478 shares of the company's stock, valued at approximately $434,774.34. This represents a 37.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alan J. Russell sold 100,000 shares of Edgewise Therapeutics stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $27.37, for a total transaction of $2,737,000.00. Following the transaction, the insider now owns 14,863 shares of the company's stock, valued at approximately $406,800.31. The trade was a 87.06 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 164,545 shares of company stock worth $4,605,305. 24.11% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on EWTX shares. Wedbush raised their price target on Edgewise Therapeutics from $44.00 to $45.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. Truist Financial boosted their target price on Edgewise Therapeutics from $33.00 to $50.00 and gave the company a "buy" rating in a report on Wednesday, November 27th. Evercore ISI increased their price target on Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. Finally, Stifel Nicolaus started coverage on shares of Edgewise Therapeutics in a research report on Wednesday, January 22nd. They set a "hold" rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.29.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.